ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Effect of Pre-Transplant Opioid Use on Post Liver Transplant Outcomes

K. Guilbert, H. Underwood, C. J. Simon

Lahey Hospital and Medical Center, Burlington, MA

Meeting: 2020 American Transplant Congress

Abstract number: B-170

Keywords: Liver, Pain

Session Information

Session Name: Poster Session B: Liver: Recipient Selection

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Impact of pre-liver transplant opioid use on post-liver transplant length of stay and clinical outcomes.

*Methods: This single-institution retrospective study included adult patients who received a liver transplant between April 2015 and November 2018. Exclusion criteria included multi-organ transplant and/or re-transplant recipients. Patients were divided into two groups: those taking opioid medications and those not taking opioid medications prior to transplantation. The primary endpoint was length of stay during the index transplant admission. The secondary endpoints compared opioid use at months 1, 3, 6, 9, and 12, patient 1-year mortality rate, 1-year graft failure rate, rejection within 1 year of transplant, ileus and small bowel obstruction during transplant admission, unplanned return to the operating room during transplant admission, and 1-month and 3-month readmission rates.

*Results: Three hundred patients met our inclusion criteria, including 243 who were not taking opioids prior to transplantation and 57 who were taking opioids prior to transplantation. Most patients included in the study were male (65%) deceased donor recipients (86.3%) with a median age of 59 and median MELD of 25 at the time of transplant. There were no statistically significant differences between the two groups. There was no statistically significant difference in length of stay post-transplant with a median of 9 days in the no-opioid group compared to 10 days in the opioid group (p=0.42). There was a statistically significant difference of opioid use post-transplant at all time-points between the two groups (discharge and months 1, 3, 6, 9, and 12). There was no difference in the mortality rate (10.3% vs 8.8%, p=1), graft failure rate (2% vs 0%, p=0.59), and 1-year rejection rate (10.5% vs 7%, p=0.62). There was no difference in ileus, small bowl obstruction, or unplanned return to the operating room. Similar readmission rates were seen between the two groups within 1 month (28.4% vs 31.6%, p=0.745) and 3 months (43.5% vs 45.6%, p=0.882).

*Conclusions: There was no significant impact of pre-transplant opioid use on length of stay, mortality, graft failure, rejection, or 1- and 3-month readmissions. We noted a strong correlation with patients who used opioids pre-transplant being more likely to continue using opioids post-transplant at all time periods examined. We noted a trend towards higher pre-transplant morphine equivalents resulting in higher opioid doses and longer duration of opioid use post-transplant. Further investigation is required to examine the impact of pre-transplant opioid use on long-term clinical outcomes.

Opioid Use Post-transplant
Opioid Use Post-transplant No-Opioid Pre-transplant Opioid Pre-transplant p-value
Discharge 67.7% 84.2% 0.0144
Month 1 32.3% 73.7% 0.0001
Month 3 10.6% 43.6% 0.0001
Month 6 5.8% 45.5% 0.0001
Month 9 3.7% 40.7% 0.0001
Month 12 2.8% 39.6% 0.0001
  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Guilbert K, Underwood H, Simon CJ. Effect of Pre-Transplant Opioid Use on Post Liver Transplant Outcomes [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/effect-of-pre-transplant-opioid-use-on-post-liver-transplant-outcomes/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences